NATIONAL INSTITUTES OF HEALTH

Cedars-Sinai researchers developed an AI method using pathology reports to automate cancer staging, speeding up clinical trial candidate selection and expanding AI's healthcare applications.

Fanaroff: Research grants from American Heart Association and National Institutes of Health; consulting fees from Abbott Laboratories. Vora: Consulting fees from Medtronic. Mehran: Institutional research grants from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi Sankyo, Medtronic, Novartis, OrbusNeich; consulting fees from Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Roivant Sciences Inc, Sanofi; consulting (no fees) for Regeneron Pharmaceuticals Inc; institutional consulting fees from Abbott Vascular, Spectranetics/Phillips/Volcano Corporation, Bristol Myers Squibb, Novartis, Watermark Research; Executive committee member for Janssen Pharmaceuticals and Bristol Myers Squibb; <1% equity in Claret Medical and Elixir Medical. Granger: Research grants from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Armetheon, AstraZeneca, US Food and Drug Administration, GlaxoSmithKline, The Medicines Company, Medtronic Foundation, Medtronic Inc, Novartis; consulting fees from Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Abbvie, Armetheon, AstraZeneca, Eli Lilly, Gilead, GlaxoSmithKline, Hoffmann-La Roche, The Medicines Company, National Institutes of Health, Novartis, Sirtex, Verseon, Apple, Medscape, LLC, Merck, Novo Nordisk, Roche Diagnostics, Rho Pharmaceuticals. Goodman: Research grant support and/or speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo, Eli Lilly, Esperion, Fenix Group International, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Novo Nordisk A/C, Pfizer, Regeneron, Sanofi, Servier, Tenax Therapeutics, Heart and Stroke Foundation of Ontario/University of Toronto, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, PERFUSE. Aronson: Employee of Bristol Myers Squibb. Windecker: Institutional research and educational grants from Abbott, Amgen, Bayer, BMS, CSL Behring, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Polares, Sinomed. Alexander: Research grants from Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, CryoLife, CSL Behring, US Food and Drug Administration, National Institutes of Health, Sanofi, VoluMetrix; consulting fees from Pfizer, Bristol Myers Squibb, AbbVie Pharmaceuticals, CSL Behring, Novo Nordisk, Portola Pharmaceuticals, Quantum Genomics, Teikoku Pharmaceuticals, VA Cooperative Studies, Zafgen. Lopes: Research grants from Bristol Myers Squibb, Pfizer, Amgen, Inc, GlaxoSmithKline, Medtronic PLC, Sanofi Aventis; consulting fees from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Bayer AG. The other authors report no conflicts.

NIH researchers developed TrialGPT, an AI algorithm that efficiently matches potential volunteers to relevant clinical trials on ClinicalTrials.gov, potentially enhancing clinical trial enrollment and medical research advancements.

NIH researchers developed TrialGPT, an AI model derived from ChatGPT, to streamline clinical trial volunteer recruitment, reducing time and maintaining accuracy. Published in Nature Communications, it aims to address the 80% failure rate in timely patient recruitment, particularly in cancer trials. TrialGPT matches patients to trials with near-human accuracy, saving clinicians 40% screening time.

NIH researchers developed TrialGPT, an AI algorithm to match potential volunteers to relevant clinical trials on ClinicalTrials.gov, enhancing trial enrollment efficiency and accuracy. The tool uses large language models to process patient summaries and identify eligible trials, reducing clinician screening time by 40% while maintaining accuracy. Selected for The Director's Challenge Innovation Award, TrialGPT aims to improve clinical trial recruitment and reduce participation barriers.

NIH's $50.1 billion FY25 budget focuses on cancer research, neuroscience, precision medicine, AI, and cybersecurity, aiming to drive healthcare advancements and improve patient outcomes.

Semaglutide, top-selling drug in 2023 with $13.8 billion in sales, is estimated to be eligible for 136.8 million US adults, based on NHANES data from 2015-2020. Eligibility criteria include diabetes, weight management, and secondary prevention of CVD. This highlights potential impact on pharmaceutical spending and urgent need for cost-reducing interventions.

UH Mānoa’s JABSOM receives $500,000 from NIH for ethical AI development in public health, expanding the ARCH Collaborative’s AI Resource Concierge for Healthcare to reduce disparities in underserved communities.

Bolder BioTechnology announced NIAID's option to fund the second year of Contract NIH-BAA-75N93023C00011, focusing on BBT-059's advanced development as a radiation medical countermeasure. The contract aims to complete GMP manufacturing, preclinical safety studies, and enable an Investigational New Drug Application filing with the FDA, totaling $3,079,369.